Bengaluru-based startup 4baseCare locked in ₹128 crore in its Series B funding round . This round aims to boost global reach in precision oncology. Follows earlier ₹90 crore close co-led by Ashish Kacholia and Lashit Sanghvi,with Yali Capital backing again .
Funds will grow 4baseCare's hospital-linked genomics lab network,enhance AI platform OncoTwin. Company wants precision oncology accessible to cancer patients in India and beyond — Middle East,Southeast Asia,Latin America,Central Asia.
4baseCare targets data diversity gap in cancer care. Developing population-specific genomic data,AI platforms. OncoTwin,their flagship solution, is clinical decision support tool. Learns from real-world clinico-genomic data. Helps oncologists make faster,informed treatment decisions.
March 2025, company’s genomics lab in Dubai Science Park got accreditation from College of American Pathologists (CAP). Ensures genomic profiling meets international quality standards for cancer patients in UAE, broader Middle East.
4baseCare also launched cancer gene panel for South Asian population. Analyzes multiple genes for cancer-related mutations. Aims to boost personalized treatment,improve outcomes.
CEO and co-founder Hitesh Goswami stressed data's transformative role in cancer care. Said, “From 2025 to 2035,cancer care will fundamentally change driven by data.” Sees funding as key step for OncoTwin capabilities.
With revenue targets ambitious,4baseCare aims for ₹100 crore in next 12 to 18 months . Already reported over ₹35 crore revenue for fiscal 2025. Startup leads in integrating advanced genomics with digital health technologies. But will they keep pace with growing demands…
